Allarity Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $13.89M
- P/E (TTM)
- –
- Dividend yield
- –
About Allarity Therapeutics
Pharmaceutical Preparations, SIC 2834
Allarity Therapeutics is a clinical-stage precision medicine pharmaceutical company developing targeted cancer therapeutics. The company focuses on its lead therapeutic candidate, stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) and tankyrases being evaluated in clinical trials for advanced ovarian cancer and relapsed small cell lung cancer. In conjunction with drug development, the business utilizes its proprietary Drug Response Predictor (DRP) companion diagnostic platform to identify patients most likely to benefit from specific treatments. It also provides DRP analysis and gene expression laboratory services to external biotechnology clients.
The company operates its clinical research across trial sites located in the United States and Europe. It also maintains external out-licensing and development partnerships, including collaboration with Chosa Oncology. Allarity Therapeutics maintains its principal executive offices in Tarpon Springs, Florida.
Summary of the business section of Allarity Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Allarity Therapeutics, Inc.
- Founded
- 2004
- Headquarters
- Boston, MA
- Address
- 24 School St., 2nd Floor 02108
- Phone
- (401) 426-4664
- Website
- allarity.com
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Wolf & Company P.C., Boston, Massachusetts
Stock & identifiers
- Ticker
- ALLR
- Exchange
- Nasdaq
- IPO date
- Apr 20, 2023
- Shares outstanding
- 16M, Aug 14, 2026
- Public float
- $14.73M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-30 reverse, Sep 11, 2024; 1-for-20 reverse, Apr 9, 2024; 1-for-40 reverse, Jun 29, 2023; 1-for-35 reverse, May 11, 2023; 1-for-35 reverse, Mar 27, 2023
- SEC CIK
- 1860657
- CUSIP
- 016744500
- ISIN
- US0167445008
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas Jensen | CEO | 596,734 |
| Jeremy R. Graff | See Remarks | 381,644 |
| Jeffrey S. Ervin | CFO | 150,000 |
| Alexander Epshinsky | CFO | 85,051 |
| Jesper Hoeiland | Director | 25,000 |
| Gerald W. McLaughlin | Director | 70,000 |
| Laura Benjamin | Director | – |
| Joseph Walter Vazzano | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had eight employees; seven of whom were full-time and one part-time.”
Corporate history
Events identified from SEC filings